Source:http://linkedlifedata.com/resource/pubmed/id/14521169
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2003-10-2
|
pubmed:abstractText |
Beta2m accumulation induces disease in patients with end-stage renal failure (ESRF). Thus, its removal from patients with ESRF appears desirable. Current dialysis technology, however, has limited effectiveness.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0391-3988
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
723-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading | |
pubmed:year |
2003
|
pubmed:articleTitle |
Beta2-microglobulin clearance with super high flux hemodialysis: an ex vivo study.
|
pubmed:affiliation |
Department of Intensive Care, Austin & Repatriation Medical Centre, Melbourne, Australia.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|